Isaac Gannon

Isaac Gannon

Auto-generated profile, based on publicly available information

Isaac Gannon

Cancer Institute, University College London, WC1E 6DD London, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MRMatteo Righi
Matteo Righi
IGIsaac Gannon
Isaac Gannon
MRMatthew Robson
Matthew Robson
SSSaket Srivastava
Saket Srivastava
EKEvangelia Kokalaki
Evangelia Kokalaki
MPMartin Pule
Martin Pule
Adoptive T-cell therapy aims to achieve lasting tumor clearance, requiring enhanced engraftment and survival of the immune cells. Cytokines are paramount modulators of T-cell survival and proliferation. Cytokine receptors signal via ligand-induced dimerization, and this principle has been hijacked utilizing nonnative dimerization domains. A major limitation of current technologies resides in the absence of a module that recapitulates the natural cytokine receptor heterodimeric pairing. To circumvent this, we created a new engineered cytokine receptor able to constitutively recreate receptor-heterodimer utilizing the heterodimerization domain derived from the IgG1 antibody (dFab_CCR). We found that the signal delivered by the dFab_CCR-IL2 proficiently mimicked the cytokine receptor heterodimerization, with transcriptomic signatures like those obtained by activation of the native IL2 receptor. Moreover, we found that this dimerization structure was agnostic, efficiently activating signaling through four cytokine receptor families. Using a combination of in vivo and in vitro screening approaches, we characterized a library of 18 dFab_CCRs coexpressed with a clinically relevant solid tumor–specific GD2-specific chimeric antigen receptor (CAR). Based on this characterization, we suggest that the coexpression of either the common β-chain GMCSF or the IL18 dFab_CCRs is optimal to improve CAR T-cell expansion, engraftment, and efficacy. Our results demonstrate how Fab dimerization is efficient and versatile in recapitulating a cytokine receptor heterodimerization signal. This module could be applied for the enhancement of adoptive T-cell therapies, as well as therapies based on other immune cell types. Furthermore, these results provide a choice of cytokine signal to incorporate with adoptive T-cell therapies.

1 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
ARAlexandros Rampotas
Alexandros Rampotas
ZWZoë C. Wong
Zoë C. Wong
IGIsaac Gannon
Isaac Gannon
CBCharlotte K. Brierley
Charlotte K. Brierley
YSYuqi Shen
Yuqi Shen
MPMartin Pule
Martin Pule
Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms (MPNs) are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin. Calreticulin mutant protein (mutCALR) binds and activates thrombopoietin receptor (TpoR) and results in the display of the mutCALR-TpoR complex on the extracellular membrane of disease-driving cells, thus exposing a therapeutic vulnerability. Here, we present a chimeric antigen receptor T cell (CAR T cell) therapy that specifically targets mutCALR+ cells, both in vitro and in vivo. The CAR T cell therapy selectively depleted mutCALR+ stem cells in samples from patients with myelofibrosis without affecting healthy stem cells and improved survival in mutCALR leukemia xenograft models. To mimic myelofibrotic marrow, we developed a human “chimeroid” model and showed no decrease in the potency of CAR T cell–mediated target cell killing even in a fibrotic TME. We also devised a method to boost the cell surface expression of mutCALR in CD34+ cells isolated from patients with accelerated/blast phase MPNs (defined as >10% blasts in the peripheral blood or bone marrow), enhancing CAR T cell targeting. This study presents a therapeutic strategy with potential to eradicate mutCALR-driven malignancies and highlights an innovative strategy to evaluate blood cancer–targeting immunotherapies in a relevant TME.

26 November 2025
Verified
Other
Open access
PDF file
MRMatteo Righi
Matteo Righi
IGIsaac Gannon
Isaac Gannon
MRMatthew Robson
Matthew Robson
SSSaket Srivastava
Saket Srivastava
EKEvangelia Kokalaki
Evangelia Kokalaki
MPMartin Pule
Martin Pule
Supplementary Table 1: Key Resources



19 July 2023
Verified
Other
Open access
PDF file
MRMatteo Righi
Matteo Righi
IGIsaac Gannon
Isaac Gannon
MRMatthew Robson
Matthew Robson
SSSaket Srivastava
Saket Srivastava
EKEvangelia Kokalaki
Evangelia Kokalaki
MPMartin Pule
Martin Pule
Supplementary Table 1: Key Resources